Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 10/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870789 | 0.87 | PTGES (0.53) | PTGESPTGS2TMEM97GABRPGABRD | |
| SCHEMBL30611207 | 0.86 | FAAH (0.55) | PTGESPTGS2FAAH | |
| SCHEMBL21153991 | 0.86 | FAAH (0.55) | PTGESPTGS2FAAH | |
| SCHEMBL6488071 | 0.86 | PTGES (0.57) | PTGESPTGS2FAAH | |
| SCHEMBL3082150 | 0.86 | PTGES (0.53) | PTGESPTGS2 | |
| SCHEMBL3101725 | 0.85 | HTR3E (0.55) | PTGESPTGS2 | |
| SCHEMBL6497353 | 0.85 | PTGES (0.54) | PTGESPTGS2 | |
| SCHEMBL24462181 | 0.82 | PTGES (0.61) | PTGESPTGS2 | |
| SCHEMBL29551098 | 0.82 | PTGES (0.61) | PTGESPTGS2 | |
| SCHEMBL3104598 | 0.81 | TRPV1 (0.52) | PTGESPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867226-B2 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6552057-B2 | In addition to 5-HT3 receptor antagonism, and inhibiting diarrhea without causing constipation as side effect; benzoxazole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0806419-B1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. | 2003-01-16 | — | — | US | disclosed |
| US-6333328-B1 | MIXING BENZOXAZOLE DERIVATIVE WITH CARRIER TO FORM ACTIVATOR COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6297246-B1 | BENZOXAZOLE DERIVATIVES; DOES NOT CAUSE CONSTIPATION AS A SIDE EFFECT. | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6037342-A | BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS | MEIJI SEIKA KAISHA, LTD (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0806419-A1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | HTR7, HTR1A, HTR3A | PTGES 2198/4885PTGS2 1585/4885TMEM97 255/4885 |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | HTR7, HTR3A, HTR1A | PTGES 2443/4885PTGS2 1814/4885TMEM97 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.